As expected, data collected in our study showed that BAK treatment markedly improved SOD and GSH-Px activities and reduced MDA content, as well as inhibited hyperglycemia-triggered ROS production, thus alleviating myocardial oxidative stress both in vivo and in vitro. The gene discussed is BAK1; the disease is Hyperglycemia.